Claims

1. Use of a peroxisome proliferator activated receptor (PPAR) modulator and a polymeric nanocarrier component in the manufacture of a medicament for the treatment of Parkinson's Disease, Alzheimer's Disease or Huntington's Disease, wherein the polymeric nanocarrier component is capable of solubilising the PPAR modulator in an aqueous medium, wherein in the polymeric nanocarrier component is a micelle forming non-ionic surfactant; wherein the medicament is to be intranasally administered; and wherein the micelle forming surfactant is selected from one or more of D-α-tocopherol polyethylene glycol 1000 succinate, PEGylated phospholipid derivatives (such as DSPE-PEG, DSPS-PEG, PLGA-PEG etc.), poloxamers (such as Lutrol F68, Lutrol F127 etc.), poly(lactic-co-glycolic acid) (PLGA), chitosan derivatives (chitosan-PEG etc.) or biodegradable polymer-PEG.

2. The use according to claim 1, wherein the polymeric nanocarrier component further comprises one or more additional materials selected from ethylphosphatidylcholine and cationic lipids, such as N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), 18:1 DGS-NTA(Ni) [1,2-dioleoyl-sn-glycero-3-[(N-(5-amino- 1-carboxypentyl)iminodiacetic acid)succinyl] or Solutol HS.

3. The use according to any preceding claim, wherein the medicament is in the form of a micellar composition.

4. The use according to claim 3, wherein the micelles have a diameter of about 30 nm or less.

5. The use according to any preceding claim, wherein the medicament is in the form of a ternary system comprising an aqueous continuous phase, the PPAR modulator and polymeric nanocarrier component being predominantly present in a disperse phase distributed therein.

6. The use according to any preceding claim which is sterile.

7. The use according to any preceding claim, wherein the PPAR modulator is a PPAR-gamma agonist or a compound having PPAR-gamma agonist activity.

8. The use according to any preceding claim, wherein the PPAR modulator is a thiazolidinedione, curcumin or resveratrol.

9. The use according to claim 8, wherein the PPAR modulator is selected from one or more of pioglitazone, rosiglitazone, lobeglitazone, ciglitazone, darglitazone, englitazone, netoglitazone, rivoglitazone, Phytocannabinoid A9-THCA and troglitazone.

10. The use according to any preceding claim, further comprising one or more pharmaceutically acceptable carriers or excipients.